斯派尔治疗

关于 Spyre Therapeutics

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which 从事 the 开发 of next-generation human enzyme therapeutics as disruptive 解决方案 for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was 成立 by George Georgiou and David G. Lowe on December 16, 2013 and is 总部位于 in Waltham, MA.

成立时间

2013

首席执行官

Dr. Cameron Turtle, D.Phil.

员工人数

102

总部地址

Waltham, Massachusetts, United States of America

财年结束日

12-31

官方网站

spyre.com

公司概况

交易所

US

股票代码

SYRE

市值排名

#1646

上市日期

1970-01-01

市值

7.37B

流通市值

6.53B

总股数

92.18M

流通股数

81.71M

行业与主题板块

浏览全部行业与主题板块